Latest Insider Transactions at Karuna Therapeutics, Inc. (KRTX)
This section provides a real-time view of insider transactions for Karuna Therapeutics, Inc. (KRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Karuna Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Karuna Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 03
2023
|
Laurie J Olson |
SELL
Open market or private sale
|
Direct |
1,000
-29.46%
|
$215,000
$215.71 P/Share
|
|
Jul 03
2023
|
Laurie J Olson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+33.44%
|
$84,000
$84.86 P/Share
|
|
Jul 03
2023
|
Jeffrey M Jonas |
SELL
Open market or private sale
|
Direct |
13,810
-43.91%
|
$2,982,960
$216.28 P/Share
|
|
Jul 03
2023
|
Jeffrey M Jonas |
BUY
Exercise of conversion of derivative security
|
Direct |
13,810
+48.27%
|
$96,670
$7.27 P/Share
|
|
Jun 20
2023
|
James Healy |
BUY
Grant, award, or other acquisition
|
Direct |
990
+2.87%
|
-
|
|
Jun 20
2023
|
David E. Wheadon |
BUY
Grant, award, or other acquisition
|
Direct |
990
+50.0%
|
-
|
|
Jun 20
2023
|
Atul Pande |
BUY
Grant, award, or other acquisition
|
Direct |
990
+50.0%
|
-
|
|
Jun 20
2023
|
Christopher J Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
990
+50.0%
|
-
|
|
Jun 20
2023
|
Jeffrey M Jonas |
BUY
Grant, award, or other acquisition
|
Direct |
990
+50.0%
|
-
|
|
Jun 20
2023
|
Laurie J Olson |
BUY
Grant, award, or other acquisition
|
Direct |
990
+50.0%
|
-
|
|
Jun 20
2023
|
Denice Torres |
BUY
Grant, award, or other acquisition
|
Direct |
990
+50.0%
|
-
|
|
Jun 14
2023
|
James Healy |
BUY
Other acquisition or disposition
|
Indirect |
8,025
+50.0%
|
-
|
|
Jun 14
2023
|
James Healy |
SELL
Other acquisition or disposition
|
Indirect |
400,000
-22.57%
|
-
|
|
May 23
2023
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,000
-4.19%
|
$2,007,000
$223.67 P/Share
|
|
May 23
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+18.56%
|
$81,000
$9.2 P/Share
|
|
Apr 20
2023
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
15,000
-38.07%
|
$3,000,000
$200.13 P/Share
|
|
Apr 20
2023
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+17.75%
|
$76,500
$9.2 P/Share
|
|
Apr 18
2023
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
30,000
-49.26%
|
$6,000,000
$200.16 P/Share
|
|
Apr 18
2023
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+33.0%
|
$270,000
$9.2 P/Share
|
|
Apr 10
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-17.45%
|
$880,000
$176.88 P/Share
|
|
Apr 10
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+14.86%
|
$45,000
$9.2 P/Share
|
|
Apr 03
2023
|
Laurie J Olson |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$181,000
$181.02 P/Share
|
|
Apr 03
2023
|
Laurie J Olson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$84,000
$84.86 P/Share
|
|
Mar 09
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-17.45%
|
$945,000
$189.51 P/Share
|
|
Mar 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+14.86%
|
$25,000
$5.45 P/Share
|
|
Feb 21
2023
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-16.44%
|
$1,140,000
$190.01 P/Share
|
|
Feb 21
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+14.12%
|
$54,000
$9.2 P/Share
|
|
Feb 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+26.78%
|
-
|
|
Feb 09
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-25.0%
|
$960,000
$192.37 P/Share
|
|
Feb 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.0%
|
$25,000
$5.45 P/Share
|
|
Feb 09
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+22.1%
|
-
|
|
Feb 09
2023
|
Andrew Craig Miller President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
12,550
+28.88%
|
-
|
|
Feb 09
2023
|
Steven M Paul |
BUY
Grant, award, or other acquisition
|
Direct |
11,400
+50.0%
|
-
|
|
Feb 06
2023
|
William P Kane Jr Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,656
+50.0%
|
-
|
|
Jan 18
2023
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
200
-0.91%
|
$40,000
$200.14 P/Share
|
|
Jan 18
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.9%
|
$1,800
$9.2 P/Share
|
|
Jan 17
2023
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
817
-3.61%
|
$164,217
$201.41 P/Share
|
|
Jan 17
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
817
+3.48%
|
$7,353
$9.2 P/Share
|
|
Jan 13
2023
|
James Healy |
SELL
Open market or private sale
|
Indirect |
6,027
-100.0%
|
$1,199,373
$199.9 P/Share
|
|
Jan 12
2023
|
James Healy |
BUY
Other acquisition or disposition
|
Indirect |
6,027
+50.0%
|
-
|
|
Jan 12
2023
|
James Healy |
SELL
Other acquisition or disposition
|
Indirect |
300,000
-14.48%
|
-
|
|
Jan 09
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.02%
|
$985,000
$197.52 P/Share
|
|
Jan 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.14%
|
$30,000
$6.36 P/Share
|
|
Jan 03
2023
|
Laurie J Olson |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$197,000
$197.48 P/Share
|
|
Jan 03
2023
|
Laurie J Olson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$84,000
$84.86 P/Share
|
|
Jan 03
2023
|
William Meury President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
38,073
+50.0%
|
-
|
|
Dec 21
2022
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
7,100
+27.9%
|
$14,200
$2.92 P/Share
|
|
Dec 16
2022
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,867
+12.93%
|
$106,803
$9.2 P/Share
|
|
Dec 09
2022
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-13.92%
|
$1,000,000
$200.76 P/Share
|
|
Dec 09
2022
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.01%
|
$40,000
$8.24 P/Share
|